Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avalo Therapeutics ( (AVTX) ) has provided an update.
On September 16, 2025, Avalo Therapeutics announced the appointment of Kevin Lind to its Board of Directors, effective October 1, 2025. Lind, a seasoned biotechnology executive with over 20 years of experience, will join the Audit Committee and has a history of successful leadership in capital markets and strategic company development. His appointment follows the resignation of June Almenoff, M.D., Ph.D., who stepped down to pursue new opportunities, effective the same date. Almenoff’s resignation was not related to any company issues, and her contributions over the past four years were acknowledged by Avalo.
The most recent analyst rating on (AVTX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.
Spark’s Take on AVTX Stock
According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.
The overall stock score for Avalo Therapeutics is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. Despite positive technical indicators suggesting bullish momentum, the negative valuation metrics due to ongoing losses weigh heavily on the stock’s attractiveness.
To see Spark’s full report on AVTX stock, click here.
More about Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. Their lead asset, AVTX-009, is undergoing a Phase 2 clinical trial for hidradenitis suppurativa (HS).
Average Trading Volume: 230,507
Technical Sentiment Signal: Sell
Current Market Cap: $155.6M
Find detailed analytics on AVTX stock on TipRanks’ Stock Analysis page.